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Abstract
Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour
predisposition syndrome characterised by predisposition to cutaneous and uterine
leiomyomata and renal cell carcinoma (RCC).
Objective: To define the clinical findings, molecular genetics, and prognosis in a
cohort of 69 families with a fumarate hydratase (FH) pathogenic variant and/or
clinical features of HLRCC.
Design, setting, and participants: Clinical and molecular findings were obtained for
185 individuals from 69 families from four UK regional genetics clinics.
Outcome measurements and statistical analysis: Ages at confirmed diagnoses, last
dates of follow-up, and molecular results were attained for probands and relatives.
To study the effect of potential ascertainment bias, phenotypes of probands and
their affected relatives were compared.
Results and limitations: A germline FH variant (19 novel and 21 known, >50%
missense variants) was identified in 68/69 probands and 90 relatives. Cutaneous
leiomyomata occurred in 90/185 (48.6%) individuals (mean age 45.9 yr) and uterine
leiomyomata in 33/107 (30.8%) females (mean age 35.0 yr). Of 185 individuals, 23
(12.4%) had a confirmed renal tumour, and histopathology where known (n = 18). Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub,
tal, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK.
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was variable: seven clear cell RCCs, nine papillary RCCs (six of type 2), one
collecting duct tumour, and one tumour with oncocytic cystic morphology.
Mean age at symptomatic RCC diagnosis was 44.0 yr and median survival was
21.0 mo. Eighty-one individuals underwent 187 renal imaging surveillance
scans; three stage 1 RCCs were detected. Mean survival of individuals diagnosed
with stage 1/2 RCC was significantly longer than those diagnosed with stage 3/4
RCC (p = 0.0004).
Conclusions: Management of HLRCC is challenging as RCC occurs in a minority of
cases but is highly aggressive. This large multicentre series has identified novel
features and evidence that renal screening in HLRCC detects early-stage RCCs.
Patient summary: We show that hereditary leiomyomatosis and renal cell cancer
is associated with a 21% lifetime risk of renal cell carcinoma (RCC; 95% confidence
interval 8.2–37.1), and renal imaging screening detects early-stage RCC.
© 2019 Published by Elsevier B.V. on behalf of European Association of Urology.
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Hereditary leiomyomatosis and renal cell cancer (HLRCC;
#150800) is a tumour predisposition syndrome characterised
by age-related predisposition to the development of cutane-
ous and uterine leiomyomata, and renal cell carcinoma (RCC)
[1]. HLRCC arises from heterozygous germline alterations of
fumarate hydratase (FH), which encodes the protein catalys-
ing the conversion of fumarate to malate in the tricarboxylic
acid cycle [2]. Homozygous germline mutations cause
metabolic disorder and fumarase deficiency (FMRD;
#606812); to date, there is no known difference between
the FH mutations causing FMRD and HLRCC, and there are no
discernable genotype-phenotype correlations for HLRCC.
HLRCC displays variable age-related penetrance with
uterine leiomyomata and cutaneous leiomyomata reported
to occur in up to 70% of affected individuals, whereas the
risk of RCC is less clear but generally estimated to be 15–20%
[1,3]. However, many previous studies have relied primarily
on index case data to attain penetrance estimates.
The uterine leiomyomata and renal tumours seen in
HLRCC typically have single or multinucleated nuclei with
large inclusion-like eosinophilic or orangiophilic nucleoli
surrounded by a clear halo [4,5]. These features have led to
HLRCC, recently being classified as a distinct subtype of RCC
[6], and are important to recognise as they may lead to new
diagnoses of HLRCC. Immunohistochemistry, although not
routinely available, to detect aberrant succination is highly
specific for FH-deficient tumours, also aiding in the
recognition of an underlying diagnosis of HLRCC [7].
HLRCC-associated RCC can be highly aggressive, and
despite uncertainty and a paucity of evidence regarding
both the magnitude of the risks of RCC and the efficacy of
screening, an international consensus group recommended
annual magnetic resonance imaging (MRI) renal imaging
surveillance in at-risk individuals [1].
The prevalence of HLRCC has been estimated to be~1 in
200 000; therefore, it is challenging to identify the large
numbers of families that might provide the information to
enable better diagnosis and management of this rare
disorder. Here, we describe the largest single cohort toPlease cite this article in press as: Forde C, et al. Q2Hereditary Le
Screening Features in a Cohort of 185 Affected Individuals. Eur Udate of HLRCC patients and family members including
greater than two-thirds nonindex cases, detailing the
clinical and molecular genetic features, renal screening,
and RCC survival.
2. Patients and methods
2.1. Clinical studies
This study comprised patients and family members attending
four NHS genetics clinics, with a likely diagnosis of HLRCC
based on clinical diagnostic criteria [1] and/or molecular data
[1]. Clinical and molecular information was collected from
clinical records for research or service evaluation studies.
Affected individuals were diagnosed by clinical examination
and routine clinical investigations. All patients gave informed
consent for genetic testing. This service evaluation study was
approved by Manchester Foundation Trust, Birmingham
Women’s and Children’s NHS Foundation Trust, St George’s
NHS Trust, and Nottingham University Hospitals NHS Trust. A
subgroup of patients additionally consented for research
studies. Clinically unaffected carriers of a known familial
mutation were included. Family members testing negative for
the familial mutation were excluded. No phenocopies were
identified. Four families were previously reported [8–10]. Data
for the age at diagnosis of RCC in HLRCC were compared with
the previously published data for age at onset of RCC in von
Hippel-Lindau (VHL) disease and familial nonsyndromic RCC
[11,12].
For individuals in whom a clinical laboratory diagnostic
report identified a germline FH variant, the previously
unreported variants were retrospectively analysed based on
the recently published criteria [13,14]. The review panel
reached a consensus decision regarding variant classifica-
tion according to the standard criteria [11] and contribution
of the variant to clinical phenotype [15].
Renal imaging screening by MRI included T1, T2, fat sat,
in and out of phase, diffusion and post-intravenous
gadolinium images, and subtraction imaging. Images were
acquired in axial and coronal planes, with slice thickness
varying between 4 and 6 mm depending on the sequence.iomyomatosis and Renal Cell Cancer: Clinical, Molecular, and
rol Oncol (2019), https://doi.org/10.1016/j.euo.2019.11.002
Table 1 – Details of confirmed cutaneous and uterine leiomyomata occurring in HLRCC cohort.
Number with confirmed
diagnosis
Means of confirmation Age at diagnosisa (yr) Cumulative prevalence to
age 75 yr (%)
Male Female Total Histology Clinical
examination
Medical
records
Mean age
(SEM)
Median Range N Male &
female
Male Female
Cutaneous leiomyomata (total cohort = 185)
All
32 58 90 54 36 3 45.9 (1.59) 45.5 18–70 82 78.0 74.9 79.9
Index
13 31 44 35 8 1 42.7b (1.89) 43 18–43 39 94.7c 100.0 92.4
Nonindex
19 22 46 19 25 2 48.7b (2.45) 47 22–79 43 68.0c 61.2 71.6
Number with confirmed
diagnosis
Means of confirmation Age at diagnosisa (yr) Cumulative prevalence
to age 75 yr (%)Histology USS/MRI Medical
records
Mean age
(SEM)
Median Range N
Uterine leiomyomata (total female cohort = 107)
All
33 12 14 7 35.0 (1.59) 35 21–63 33 42.1
Index
17 7 5 5 32.41d (2.02) 32 21–52 17 53.6e
Nonindex
16 7 7 2 37.88d (2.90) 37 22–63 16 33.6e
HLRCC = hereditary leiomyomatosis and renal cell cancer; MRI = magnetic resonance imaging; SEM = standard error of the mean; USS = ultrasound scan.
a Where age was known.
b Mean age comparison of cutaneous leiomyomata, index with nonindex cases, t = 1.89, p = 0.06.
c Comparison of cumulative prevalence cutaneous leiomyomata, index with nonindex cases, across all ages, x2 = 12.14, p = 0.0005.
d Mean age comparison (uterine leiomyomata), index with nonindex cases, t = 1.56, p = 0.13.
e Comparison cumulative prevalence uterine leiomyomata, index with nonindex cases, across all ages, x2 = 4.72, p = 0.0298.
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Committee Cancer Staging, seventh edition [16].
2.2. Molecular genetics studies
DNA was extracted from peripheral blood by standard
methods and laboratory analysis undertaken by Sanger and/
or next-generation sequencing according to the relevant
protocols in the diagnostic laboratory (further details are
available on request).
2.3. Statistical analyses
Statistical analysis was undertaken using Graphpad Quick
Calcs, Graphpad Prism version 7, and SPSS version
20. Statistical significance was considered at 5%.
3. Results
3.1. Previous studies of HLRCC
We documented previous clinical studies of HLRCC (Sup-
plementary Table 1). All had a smaller cohort number than
that currently reported, with the larger studies having a
high proportion of index cases.
3.2. Clinical features
There were 185 individuals (107 female and 78 male
patients) from 69 families with a clinical and/or molecularPlease cite this article in press as: Forde C, et al. Q2Hereditary Le
Screening Features in a Cohort of 185 Affected Individuals. Eur Udiagnosis of HLRCC. The 69 families comprised (1) 57 new
index case presentations (45 with cutaneous lesions, seven
with a personal or family history of RCC, and five with a
personal history of uterine fibroids), (2) 11 families with a
diagnosis of HLRCC had been made in another centre, and
(3) a single family with confirmed biallelic FH inactivation
causing fumarase deficiency [8]. Mean age at diagnosis of
HLRCC in 54 index cases (three ages unknown) was 45.2 yr
(median = 46.5 yr, range = 17–70 yr, standard error of the
mean [SEM] = 1.6).. Considering the non-index case pre-
sentations, there were 77 first-, 31 second-, and 14 third-
degree relatives (six individuals’ relationship to index case
was unknown).
3.3. Cutaneous and uterine leiomyomata
Of 185 individuals from 55 families, 90 (48.6%) had
confirmed cutaneous leiomyomata, with an age-related
prevalence to age 75 yr of 78.0% (Table 1, Fig. 1A, and
Supplementary Table 2).
Thirty-three females from 26 families (33/107 = 30.8%)
had confirmed uterine leiomyomata, with an age-related
prevalence of 42.1% by age 75 yr (Table 1 and Fig. 1B).
3.4. Renal lesions
Of 185 individuals, 23 (12.4%; 13 males and 10 females;
20 symptomatic presentations and three screen
detected) individuals had confirmed (Cancer Registry/
histological records) renal tumours (Supplementaryiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and
rol Oncol (2019), https://doi.org/10.1016/j.euo.2019.11.002
Fig. 1 – Age-related prevalence of cutaneous and uterine leiomyomata
in HLRCC cohort (numbers of individuals at risk shown below graph).
(A) Age-related prevalence of cutaneous leiomyomata in males and
females. (B) Age-related prevalence of uterine leiomyomata in females.
HLRCC = hereditary leiomyomatosis and renal cell cancer.
Fig. 2 – Clinical features of RCCs diagnosed in HLRCC cohort. (A) Histogram show
within the HLRCC cohort as compared with VHL disease, FcRCC, and sporadic RCC
Meier curve showing overall survival following symptomatic diagnosis of RCC in 
interval; FcRCC = familial clear cell RCC; HLRCC = hereditary leiomyomatosis and r
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by family history (all overseas) but unconfirmed were
excluded.
Histological subtype of renal tumour was known in 18/23
cases and comprised seven clear cell renal cell carcinomas
(CCRCCs), six papillary type 2 RCCs, three papillary RCCs (no
further subclassification available), one collecting duct RCC,
and one tumour showing an oncocytic cystic morphology.
All were unifocal except for one papillary RCC that was
multifocal.
3.5. Symptomatic presentations of RCC
Seven individuals presented with stage 4 disease, two with
stage 3 disease, four with stage 2 disease, and one with stage
1 disease. Mean maximum diameter of RCC, where known,
was 93.8 mm (n = 5, median = 88 mm, range = 70–136 mm,
SEM = 11.89). Mean age of symptomatic presentation of RCC
was 44.0 yr, significantly younger than both sporadic RCC (p
= <0.0001) and familial non-VHL CCRCC (p = 0.0080), but
similar to that associated with symptomatic presentation in
VHL disease [11,12] (Fig. 2A and Table 2). Age-related
prevalence of renal cancer was 20.8% by age 75 yr (Fig. 2B,
and Supplementary Tables 2 and 4) and mean survival
following diagnosis of symptomatic RCC was 38.1 mo
(Fig. 2C and Table 2).
A prospective symptomatic RCC occurred in a 49-yr-old
female who presented with a pT3a RCC (Fig. 3A) followinging age at diagnosis of symptomatic presentation of RCC in 19 individuals
 [11,12]. (B) Age-related prevalence of RCC in HLRCC cohort. (C) Kaplan-
19 individuals (solid line; 95% CIs indicated by dotted lines). CI = confidence
enal cell cancer; RCC = renal cell carcinoma; VHL = von Hippel-Lindau.
iomyomatosis and Renal Cell Cancer: Clinical, Molecular, and
rol Oncol (2019), https://doi.org/10.1016/j.euo.2019.11.002
Table 2 – Details of screen detected and symptomatic RCCs (excluding oncocytic-cystic lesion as not RCC) occurring within the HLRCC cohort.
Features of Symptomatic RCCs
Age at diagnosis Mean age
diagnosis,
yr (SEM)
Na Range (yr) Median (yr) Mean age at diagnosis comparison (yr)
Sporadic RCCb Symptomatic VHL
diseasec
Symptomatic FCRCCd
All 44.0
(3.5)
19 14–79 44 61.0
t =4.6580
p  0.0001
46.2
t = 0.6425
p = 0.5234
53.2
t =2.6838
p= 0.0080
Index 41.1e (4.75) 8 17–54 43.5 – – –
Nonindex 46.0e (4.98) 11 14–79 42 – – –
Survival of symptomatic RCCs Stage 1/2 disease Stage 3/4 disease
Mean survival, mo (SEM) N+ 95% CIs Median survival (mo) Mean survival, mo (SEM) Number of cases Mean survival,
mo (SEM)
Number of cases
38.1 (15.7) 19 7.2–68.9 21.0 80.7f (16.6) 8 15.8f (3.9) 9 g
Screen-detected RCCs
Age at
detection (yr)
Sex Screening
scan number
Imaging features Surgery Pathology Stage Status and
censoring point
Individual #1 30 M 4 MRI: complex renal
cyst with enhancement
Partial nephrectomy Fuhrman grade 1
1 cm CCRCC
pT1a Alive, 42 mo
Individual #2 43 F 1 MRI: complex cystic
lesion upper pole
CT: lesion suspicious for RCC
Partial nephrectomy Fuhrman grade 3
4.4 cm CCRCC
pT1b Alive, 18 mo
Individual #3 h 11 M 1 USS: renal mass
CT: soft tissue mass lower
pole right kidney
Total nephrectomy Fuhrman grade 2
6.5 cm papillary RCC
pT1b Alive, 101 mo
CCRCC= clear cell RCC; CI = confidence interval; CT = computed tomography; df =degree of freedom; F = female; FCRCC = familial clear cell RCC; HLRCC =hereditary leiomyomatosis and renal cell cancer; HR=hazard ratio;
M=male; MRI =magnetic resonance imaging; RCC = renal cell carcinoma; SEM=standard error of the mean; USS =ultrasound scan; VHL= von Hippel-Lindau.
a Number of cases where age at diagnosis known.
b Maher et al [11].
c Maher et al [33].
d Woodward et al [12].
e Mean age comparison, t = 0.68, p = 0.50.
f Mean survival comparison: HR=14.42, 95% CIs =4.03–51.58, x2 = 12.6, df = 1, p = 0.0004.
g All patients deceased by 36 mo after diagnosis.
h Alrashdi et al [9].
E
 U
 R
 O
 P
 E
 A
 N
 U
 R
 O
 L
 O
 G
 Y
 O
 N
 C
 O
 L
 O
 G
 Y
 X
 X
 X
 (
 2
 0
 1
 9
 )
 X
 X
 X
 –
 X
 X
 X
 
5
EU
O
-287;
 N
o.
 of
 Pages
 9
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 Ford
e
 C
,
 et
 al.
 Q
2H
ered
itary
 Leiom
yom
atosis
 an
d
 R
en
al
 C
ell
 C
an
cer:
 C
lin
ical,
 M
olecu
lar,
 an
d
Screen
in
g
 Featu
res
 in
 a
 C
oh
ort
 of
 185
 A
ffected
 In
d
ivid
u
als.
 Eu
r
 U
rol
 O
n
col
 (2019),
 h
ttp
s://d
oi.org/10.1016/j.eu
o.2019.11.0
02
Fig. 3 – Prospective symptomatic presentation of RCC. (A) Contrast-enhanced coronal reformat CT at diagnosis showing a large complex mass at the
upper pole of the left kidney, highly suggestive of an RCC (arrowed, upper panel) and a suspicious lymph node (arrowed, lower panel). (B) H&E
histological stain showing dominant papillary architecture at low power (upper panel) with large prominent nucleoli at high power (lower panel 20T,
inset 40T). (C) Coronal reformat image of contrast-enhanced CT 1 yr following the initial presentation and left radical nephrectomy. There is omental
caking (solid arrow), ascites (unfilled arrow), and solid peritoneal masses (arrow head) in keeping with malignant peritoneal disease. (D) H&E
histological stain (20T) of peritoneal biopsy demonstrating metastatic RCC with papillary architecture and large dominant nucleoli. CT = computed
tomography; H&E = haematoxylin and eosin; RCC = renal cell carcinoma.
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EUO-287; No. of Pages 9the diagnosis of HLRCC in a relative. Histological review
following complete nephrectomy demonstrated a 70  50
 60 mm Fuhrman grade 3 papillary RCC (no subtype given;
Fig. 3B). Subsequent review in the genetics clinic noted the
presence of cutaneous leiomyomata, a history of uterine
fibroids, and the presence of a germline FH mutation
(c.301C > T; p.Arg101*). Six months after nephrectomy, she
developed liver metastases followed by peritoneal metas-
tases and omental caking, and died 14 mo after the initial
diagnosis (Fig. 3C and 3D).Please cite this article in press as: Forde C, et al. Q2Hereditary Le
Screening Features in a Cohort of 185 Affected Individuals. Eur U3.6. Renal imaging screening
Eighty-one individuals with no personal history of renal
tumours from 35 families with a diagnosis of HLRCC
underwent screening imaging, and three presymptomatic
RCCs were detected (Table 2 and Supplementary Table 5).
Twenty-one different additional radiological findings (none
required invasive investigation) were detected in 62 indi-
viduals, including 41 individuals with renal cysts (Supple-
mentary Table 6).iomyomatosis and Renal Cell Cancer: Clinical, Molecular, and
rol Oncol (2019), https://doi.org/10.1016/j.euo.2019.11.002
Fig. 4 – Survival (in months) after the diagnosis of HLRCC-associated
RCC in this cohort following diagnosis at stage 1/2 disease (bold dotted
line; 95% CIs indicated by solid lines) versus stage 3/4 disease (broken
line; 95% CIs indicated by fine dotted lines). CI = confidence interval;
HLRCC = hereditary leiomyomatosis and renal cell cancer; RCC = renal cell
carcinoma.
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Considering both screen-detected and symptomatic RCC
presentations, mean survival of individuals diagnosed with
stage 3 or 4 RCC was significantly shorter at 15.8 mo (all nine
of nine patients deceased at 36 mo) as compared with
80.7 mo for individuals diagnosed with stage 1 or 2 RCC
(Fig. 4 and Table 2).
3.8. Other cancer diagnoses
Twelve individuals from eight families had confirmed
diagnoses (medical records/Cancer Registry) of a total of
11 different non-RCC cancers, with three individuals having
two cancer diagnoses (Supplementary Table 7).
3.9. Molecular genetic testing
In 68/69 families, an underlying FH variant was detected
(one family declined testing). In the 68 families, 19 different
novel FH variants were detected in 19 families (nine
missense, four nonsense, two frameshift, one in-frame
deletion-insertion, one frame-shift deletion-insertion, one
in frame duplication, and one splice site; Supplementary
Table 8). Although many of these FH variants had been
detected in the families prior to the introduction of the
American College of Medical Genetics and Genomics
(ACMG) guidelines for variant interpretation into the UK
[14,15], we undertook a retrospective ACMG classification of
these 19 novel variants, finding 11 to be likely pathogenic
and eight pathogenic.
For the remaining 49 families in which testing was
undertaken, 21 non-novel FH variants were identified
(12 missense, three nonsense, three frameshift, one in-
frame duplication, one in-frame deletion, and one
multiexon deletion) with 10/21 variants occurring in
more than one family (Supplementary Table 9). Two of
21 variants occurring in three families, c.521C > G; p.
Pro174Arg and c.1431_1433dupAAA; p.Lys477dup
(including the family in our cohort with fumarasePlease cite this article in press as: Forde C, et al. Q2Hereditary Le
Screening Features in a Cohort of 185 Affected Individuals. Eur Udeficiency), had been described previously in recessive
fumarase deficiency but not, to our knowledge, in the
heterozygous state causing HLRCC.
4. Discussion
This study is the largest single clinical and molecular study
of HLRCC to date, involving 185 individuals from 69 families
(mean 2.68 cases/family). Compared with other recent
studies with a lower mean number of cases per family (1.60)
[3], our series has less ascertainment bias (probands:
nonprobands = 1:2.25) and more detailed clinical informa-
tion, and should provide more accurate estimates of tumour
risks.
Whilst the penetrance for cutaneous and uterine
leiomyomata is reported as being upward of 70% [3], our
study found 48.1% of individuals to have cutaneous
leiomyomata (cumulative incidence 51% by 50 yr and 76%
by 71 yr) and 28% of females to have uterine leiomyomata
(cumulative incidence 37% by 50 yr and 42% by 70 yr). This
likely arises from both our strict inclusion criteria necessi-
tating confirmed diagnoses and less than one-third of our
cohort being accounted for by index cases. We cannot
exclude that there may be under-reporting and underdiag-
nosis of these lesions; however, given their benign nature, it
would be difficult to justify regular clinical follow-up and
invasive imaging to attain exact affected/unaffected figures.
Of all individuals, 12.4% developed renal tumours. HLRCC
was classically associated with papillary type 2 RCC [17];
however, more recently a wider spectrum of renal tumour
histology has been described [4,7], which our data support.
Many of our cases predate the 2016 classification of renal
tumours, whereby HLRCC associated RCC is a distinct entity
with characteristic histological appearance [6]. If it were
possible to re-examine these cases, it would be intriguing to
see whether they match this classification. Mean age at
diagnosis of symptomatic RCC was similar to that reported
previously [1,3] and in VHL disease [11]. However, whilst
typically in familial RCC, there is a predisposition to the
development of multifocal RCCs [18], patients in this cohort
presenting with symptomatic RCCs typically had large
unifocal tumours.
The propensity to develop large aggressive unifocal
tumours in HLRCC has been recognised previously [4,17]
and may have some bearing on the poor survival. Median
survival of symptomatic RCC was only 14 mo, with all nine
patients presenting with stage 3/4 disease having died at
36 mo after the diagnosis, similar to that reported
previously [3].
Why these tumours are so aggressive is unclear but is
recognised. Considering all RCCs with an undifferentiated
histological appearance, those associated with FH deficien-
cy have been shown to have worst clinical outcome
[19]. Similarly, our data concur with that from The Cancer
Genome Atlas where median survival for CpG island
methylator phenotype RCCs, previously shown to be
present in FH-deficient RCCs, is <1 yr [20,21].
Accumulation of fumarate has also been shown to be
associated with multiple protumourigenic mechanismsiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and
rol Oncol (2019), https://doi.org/10.1016/j.euo.2019.11.002
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dohypoxia) [22], increased expression of target genes of the
NRF2 oncogenic transcription factor [23,24], epigenetic
alterations (DNA and histone methylation) [25], promotion
of epithelial to mesenchymal transition [26], and impaired
homologous recombination DNA repair activity [27]. Eluci-
dation of these dysregulated cellular pathways provides
insights into potential therapeutic options for metastatic
FH-deficient RCC such as inhibitors of downstream targets
of the HIF activation pathway or PARP inhibitors.
Whilst targeted treatments are effective in improving
survival in cancer medicine, cure is rarely achieved, and
cancer prevention or early detection strategies are consid-
ered most likely to enable curative intervention [28]. Thus,
renal surveillance imaging, preferably by MRI with 1–3 mm
slices, similar to that in other familial RCC predisposition
syndromes is recommended [1]. However, the efficacy of
such surveillance has not, to our knowledge, been
investigated previously. We demonstrated that annual renal
surveillance imaging resulted in earlier-stage tumour
detection. Whilst our numbers were too small to demon-
strate a survival benefit in screened individuals, the three
individuals with screen-detected RCCs were diagnosed with
stage 1 disease. We also demonstrated a clear survival
benefit for individuals diagnosed with stage1/2 versus stage
3/4 disease. Based on these findings, we support the
previous consensus recommendation of annual renal
imaging screening, by MRI, commencing at age 10 yr to
enable early RCC detection in HLRCC [1].
Our data suggest that renal imaging screening in HLRCC
is sensitive and specific. Three RCCs were diagnosed; there
were no interval cancers, and none of the additional
findings required invasive investigation.
Assuming a 21% RCC risk to age 70 yr and poor outcomes
from symptomatic RCC presentation, our data suggest that
as few as five patients with HLRCC would need to be
screened to save one life (assuming early detection and
treatment were curative). Whilst further data and a detailed
health economic analysis are required to determine a
definitive cost-benefit analysis for RCC screening in HLRCC,
the available data suggest that the cost of a screening
programme might be less than the cost of treating an
individual with limited life expectancy presenting with
advanced disease.
Whilst germline FH mutations have also been described
in approximately 1% individuals presenting with phaeo-
chromocytoma/paraganglioma (PPGL) only, and PPGL has
been reported in 1% of HLRCC cases [3,29], none in this
cohort developed a PPGL. Screening for PPGL in asymptom-
atic HLRCC patients is not routinely undertaken in the UK,
which our data would support.
In almost one-third of our families, a novel FH variant
was detected. Using ACMG guidance, we classified these
variants as being either likely pathogenic or pathogenic. We
found no evidence of any genotype-phenotype correlation
in keeping with previous studies.
Of the previously described mutations, two (c.521C > G;
p.Pro174Arg, c.1431_1433dupAAA;p.Lys477dup) have been
described in fumarase deficiency rather than in HLRCCPlease cite this article in press as: Forde C, et al. Q2Hereditary Le
Screening Features in a Cohort of 185 Affected Individuals. Eur U[8,30]. The first was identified in two unrelated individuals,
one of whom presented with fumarase deficiency and
paternal partial isodisomy of chromosome 1 [8]. The father
had two skin lesions removed previously, but we were
unable to clarify their nature.
We detected the FH variant c.1431_1433dupAAA;p.
Lys477dup in two families with RCC only and no other
features of HLRCC. This variant has previously been reported
in fumarase deficiency [30] and an isolated case of ovarian
cystadenoma [31], and is present in neither gnomAD
(https://gnomad.broadinstitute.org/) nor ClinVar (https://
www.ncbi.nlm.nih.gov/clinvar/). Therefore, this may repre-
sent either a rare FH allele predisposing to RCC or, given its
location outside of the known functional domains [32], a
rare coincidental variant.
5. Conclusions
This is the single largest clinical and molecular study of
HLRCC. Our data demonstrate that early diagnosis of HLRCC,
with screening being offered to at-risk individuals, provides
opportunities for disease prevention in this highly aggres-
sive cancer predisposition syndrome.
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